Details of the Drug
General Information of Drug (ID: DM05F1Z)
| Drug Name |
ENRASENTAN
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Synonyms | SB-217242; Enrasentan; (+)-(1S,2R,3S)-3-[2-(2-Hydroxyethoxy)-4-methoxyphenyl]-1-(3,4-methylenedioxyphenyl)-5-propoxyindane-2-carboxylic acid | ||||||||||||||||||
| Indication |
|
||||||||||||||||||
| Drug Type |
Small molecular drug
|
||||||||||||||||||
| Structure |
![]() |
||||||||||||||||||
| 3D MOL | 2D MOL | ||||||||||||||||||
| #Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 506.5 | |||||||||||||||||
| Logarithm of the Partition Coefficient (xlogp) | 4.6 | ||||||||||||||||||
| Rotatable Bond Count (rotbonds) | 10 | ||||||||||||||||||
| Hydrogen Bond Donor Count (hbonddonor) | 2 | ||||||||||||||||||
| Hydrogen Bond Acceptor Count (hbondacc) | 8 | ||||||||||||||||||
| Chemical Identifiers |
|
||||||||||||||||||
| Cross-matching ID | |||||||||||||||||||
| Drug-Molecule Activity Atlas (DMA)NEW | Click to Jump to the Detailed DMA Information of This Drug | ||||||||||||||||||
Molecular Interaction Atlas of This Drug
![]() Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
| The Studied Disease | Pulmonary arterial hypertension | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ICD Disease Classification | BB01.0 | |||||||||||||||||
|
||||||||||||||||||
| Molecular Expression Atlas (MEA) | ||||||||||||||||||


